Search Results - "Veldurthy, Aditya"

The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes by Veldurthy, Aditya, Patz, Michaela, Hagist, Susanne, Pallasch, Christian P., Wendtner, Clemens-Martin, Hallek, Michael, Krause, Günter

“…Src family kinases (SFKs) were described to be overexpressed in chronic lymphocytic leukemia (CLL). We wished to examine the effects of the Src and Abl kinase…”
Get full text

1.22 Comparative Assessment of Two Kinase Inhibitors, Sorafenib and Dasatinib, on CLL Cells by Kuckertz, Mirjam, Patz, Michaela, Veldurthy, Aditya, Hallek, Michael, Krause, Günter

Get full text

Erufosine, a novel alkylphosphocholine, induces apoptosis in CLL through a caspase-dependent pathway by Königs, Sonja Katharina, Pallasch, Christian Philipp, Lindner, Lars Hartwin, Schwamb, Janine, Schulz, Alexandra, Brinker, Reinhild, Claasen, Julia, Veldurthy, Aditya, Eibl, Hansjoerg, Hallek, Michael, Wendtner, Clemens-Martin

“…Abstract The alkylphosphocholine (APC) erufosine is a synthetic phospholipid analogue with antineoplastic activity. APC are known to interact with lipid…”
Get full text

Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells by Kuckertz, Mirjam, Patz, Michaela, Veldurthy, Aditya, Gehrke, Iris, Claasen, Julia, Frenzel, Lukas P, Wendtner, Clemens-Martin, Hallek, Michael, Krause, Günter

“…With sorafenib displaying the highest affinities for Flt3, VEGFR (vascular endothelial growth factor receptor) and Raf and dasatinib for Abl and Src kinases,…”
Get more information

The Src-Abl Kinase Inhibitor Dasatinib (BMS-354825) Shows Anti-Proliferative and Anti-Apoptotic Effects in Chronic Lymphocytic Leukemia (CLL) Cells In Vitro by Veldurthy, Aditya, Patz, Michaela, Pallasch, Christian P., Wendtner, Clemens M., Hallek, Michael, Krause, Gunter F.

“…Introduction: Dasatinib is an ATP competitive, dual-specific Src-Abl kinase inhibitor used for the treatment of imatinib-resistant Bcr-Abl-positive leukemias…”
Get full text